Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
Completed · Phase 3 · Has a placebo group
Conditions studied: Precancerous Condition
In brief
This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer
Key facts
- Study ID
- NCT00118365
- Run by
- National Cancer Institute (NCI)
- People needed
- 375
- Starts
- 1998-07-01
- Expected to finish
- 2008-08-01
- Last updated by the study team
- 2015-01-22
Who can join
Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California Medical Center At Irvine-Orange Campus — Orange, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.